NCT05713318

A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Huahui Health · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled Phase 2 study in participants over the age of 18 years with mild COVID-19. The main purpose of this study is to evaluate the effect on viral load clearance and clinical recovery, and safety of HH-120 nasal spray in participants over the age of 18 years with mild COVID-19 (according to the FDA definition, 2021).

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	HH-120 nasal spray	Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.
DRUG	HH-120 nasal spray	Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.
DRUG	Placebo Comparator	Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.
DRUG	Placebo Comparator	Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.

Timeline

• Start date: 2023-01-18
• Primary completion: 2023-06-19
• Completion: 2023-06-19
• First posted: 2023-02-06
• Last updated: 2024-10-10

Locations

16 sites across 1 country: China